BigHat Biosciences, a biotechnology company, has entered a strategic collaboration with Eli Lilly and Company through which it will deploy its Milliner platform, a suite of machine learning (ML) technologies integrated with a synthetic biology-based high-speed wet lab, to design and engineer therapeutic antibodies. BigHat and Lilly will collaborate to design and discover next-generation antibodies for up to two antibody therapeutic programs. This partnership aims to design, engineer, and deve...